Physician profile
Philip C Comp
NPI 1790754729
$1,092.20
in general payments reported to CMS, 2019-2025
24 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $19.54 · 2022: $86.99 · 2023: $76.34 · 2024: $212 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $142.15 | 2024-2025 | Vanflyta, Injectafer, Enhertu |
| Incyte Corporation | $112.45 | 2019-2020 | |
| Genentech USA, INC. | $105.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $103.66 | 2019 | |
| Amarin Pharma, INC. | $76.34 | 2023 | |
| Scpharmaceuticals INC. | $67.33 | 2024 | |
| Novo Nordisk INC | $65.61 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.21 | 2024-2025 | Iclusig |
| Sanofi-Aventis U.S. LLC | $45.14 | 2024-2025 | |
| Legend Biotech USA INC. | $40.07 | 2024-2025 | Carvykti |
| Merck Sharp & Dohme LLC | $38.77 | 2025 | Keytruda |
| Alnylam Pharmaceuticals INC. | $25.72 | 2024 | Givlaari |
| Adc Therapeutics America, INC. | $22.31 | 2025 | |
| Beone Medicines USA, INC. | $22.22 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $21.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $18.84 | 2025 | Fibryga |
| Astrazeneca Pharmaceuticals LP | $17.87 | 2025 | |
| Syndax Pharmaceuticals, INC. | $17.72 | 2025 | |
| Stemline Therapeutics INC. | $17.40 | 2025 | Orserdu |
| Bard Peripheral Vascular, INC. | $17.33 | 2025 | Trek |
| Geron Corporation | $14.66 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $14.66 | 2024 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $14.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Comp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.